| Literature DB >> 27757145 |
Abstract
Pregnancy in the setting of type 1 diabetes is associated with an increased risk of adverse outcomes for both mother and fetus. Adequate glycaemic control has been shown to result in improved outcomes, but the strict glycaemic targets required in pregnancy are often difficult to achieve. The development of novel technologies for insulin delivery aim to assist in achieving excellent glycaemic control, while attempting to minimize the significant risk of hypoglycaemia that exists in pregnancy. This review will discuss the use of insulin pump therapy, continuous glucose monitoring and closed loop insulin delivery in the setting of pregestational diabetes, highlighting some of the potential advantages of these technologies. Novel insulin delivery devices have been shown to be safe in the setting of pregnancy, but proper randomized controlled trials are still needed to determine if they are superior to traditional insulin delivery mechanisms.Entities:
Keywords: Type 1 diabetes; clinical pharmacology; insulin pump; insulin therapy; pregnancy
Year: 2013 PMID: 27757145 PMCID: PMC5052780 DOI: 10.1258/OM.2012.120026
Source DB: PubMed Journal: Obstet Med ISSN: 1753-495X